Skip to main content
SpringerLink
Log in

Journal Watch

  • Update
  • Published:
Pharmaceutical Medicine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

Reference

  • Gerber A, Stock S, Dintsios C-M. Reflections on the changing face of German pharmaceutical policy: how far is Germany from value-based pricing? [editorial]. Pharmacoeconomics 2011; 29 (7): 549–53

    Article  PubMed  Google Scholar 

Reference

  • Sullivan W, Payne K. The appropriate elicitation of expert opinion in economic models: making expert data fit for purpose. Pharmacoeconomics 2011; 29 (6): 455-9 Gandjour A. Prioritizing comparative effectiveness research: are drug and implementation trials equally worth funding? Pharmacoeconomics 2011; 29 (7): 555–61

    Google Scholar 

Reference

  • Eckermann S, Willan AR. Presenting evidence and summary measures to best inform societal decisions when comparing multiple strategies. Pharmacoeconomics 2011; 29 (7): 563–77

    PubMed  Google Scholar 

Reference

  • Schumock GT, Lee TA, Joo MJ, et al. Association between leukotriene-modifying agents and suicide: what is the evidence? Drug Saf 2011; 34 (7): 533–44

    Article  PubMed  Google Scholar 

Reference

  • Lewis JH. The risk of ischaemic colitis in irritable bowel syndrome patients treated with serotonergic therapies. Drug Saf 2011; 34 (7): 545–65

    Article  PubMed  CAS  Google Scholar 

Reference

  • Tomé AM, Filipe A. Quinolones: review of psychiatric and neurological adverse reactions. Drug Saf 2011; 34 (6): 465–88

    Article  PubMed  Google Scholar 

Reference

  • Schiffelers RM, van der Vaart TK, Storm G. Neovascular age-related macular degeneration: opportunities for development of first-in-class biopharmaceuticals. Biodrugs 2011; 25 (3): 171–89

    Article  PubMed  CAS  Google Scholar 

Reference

  • Ernst E, Hung SK. Great expectations: what do patients using complementary and alternative medicine hope for? Patient 2011; 4 (2): 89–101

    Article  PubMed  CAS  Google Scholar 

Reference

  • Galárraga O, Wirtz V, Figueroa-Lara A, et al. Unit costs for delivery of antiretroviral treatment and prevention of mother-to-child transmission of HIV: a systematic review for low- andmiddle-income countries. Pharmacoeconomics 2011; 29 (7): 579–99

    PubMed  Google Scholar 

Reference

  • Stafinski T, Menon D, Philippon DJ, et al. Health technology funding decisionmaking processes around the world: the same, yet different. Pharmacoeconomics 2011; 29 (6): 475–95

    Article  PubMed  Google Scholar 

Reference

  • Hoggatt J. Hot ortho-biologic topics at AAOS 2011: platelet-rich plasma and related growth factors generate excitement. Biodrugs 2011; 25 (3): 197–202

    Article  PubMed  Google Scholar 

Reference

  • Théophile H, Schaeverbeke T, Miremont-Salamé G, et al. Sources of information on lymphoma associated with anti-tumour necrosis factor agents: comparison of published case reports and cases reported to the French pharmacovigilance system. Drug Saf 2011; 34 (7): 577–85

    Article  PubMed  Google Scholar 

Reference

  • van Dijk-de Vries AN, Duimel-Peeters IGP, Vrijhoef HJM. An instrument to assess the needs of patients with type 2 diabetes mellitus for health-promotion activities. Patient 2011; 4 (2): 115–23

    Article  PubMed  Google Scholar 

Reference

  • Diaby V, Dié Kakou H, Lachaine J. Eliciting preferences for reimbursed drugs selection criteria in Côte d’Ivoire. Patient 2011; 4 (2): 125–31

    Article  PubMed  Google Scholar 

Reference

  • Iskedjian M, Covert DW, Walker JH. Persistence with prostaglandin agonist use with and without adjunctive therapy for glaucoma patients: a Canadian populationbased analysis. Patient 2011; 4 (2): 133–41

    Article  PubMed  Google Scholar 

Reference

  • Krol M, Papenburg J, Koopmanschap M, et al. Do productivity costs matter? The impact of including productivity costs on the incremental costs of interventions targeted at depressive disorders. Pharmacoeconomics 2011; 29 (7): 601–19

    PubMed  Google Scholar 

Reference

  • Leidl R, Reitmeir P. A value set for the EQ-5D based on experienced health states: development and testing for the German population. Pharmacoeconomics 2011; 29 (6): 521–34

    Article  PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Journal Watch. Pharm Med 25, 269–277 (2011). https://doi.org/10.1007/BF03256869

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03256869

Search

Navigation